Low-dose acebutolol given once daily in the treatment of chronic angina pectoris

I L Piña1, E V Smith, D J Weidler

  • 1Division of Cardiology, University of Miami School of Medicine, Florida.

Insights

Once-daily acebutolol effectively manages chronic stable angina pectoris. This beta blocker significantly improved exercise hemodynamics and reduced ST depression without adverse effects.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Acebutolol is a beta-1 selective beta blocker with intrinsic sympathomimetic activity.
  • It is effective for chronic angina pectoris with multiple daily doses.

Purpose of the Study:

  • To evaluate the long-term effects of once-daily acebutolol (400 mg) versus placebo.
  • Assess impact on exercise hemodynamics, ST segment depression, and rate pressure product.

Main Methods:

  • Eleven patients with hypertension and chronic angina pectoris were enrolled.
  • A randomized, placebo-controlled study was conducted.
  • Exercise treadmill tests were used for objective measurements.

Main Results:

  • Once-daily acebutolol significantly reduced peak heart rate, systolic blood pressure, and rate pressure product during exercise.
  • Significant reduction in ST segment depression was observed with acebutolol.
  • No significant adverse effects were reported during the study.

Conclusions:

  • Once-daily acebutolol (400 mg) is efficacious for chronic stable angina pectoris.
  • This dosing regimen improves exercise hemodynamics and reduces ischemic indicators.
  • Acebutolol offers a convenient once-daily treatment option for angina.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...